Obesity and treatment of prostate cancer: What is the right dose of lupron depot? [3]

Clinical Cancer Research

Volumn 13, Issue 13, 2007, Pages 4027-

  Agarwal, Neeraj ^a   Fletcher, Deborah ^a   Ward, John ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GONADORELIN AGONIST; LEUPRORELIN; TESTOSTERONE;

ADIPOSE TISSUE; BODY MASS; DRUG DEGRADATION; DRUG EFFECT; DRUG FORMULATION; HALF LIFE TIME; HUMAN; LETTER; OBESITY; PRIORITY JOURNAL; PROSTATE CANCER; TESTOSTERONE BLOOD LEVEL; TREATMENT RESPONSE;

BODY MASS INDEX; BODY WEIGHT; DRUG ADMINISTRATION SCHEDULE; HUMANS; LEUPROLIDE; MALE; OBESITY; PEPTIDES; PROSTATIC NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 34447125676     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0788     Document Type: Letter

References (5)

1. Smith MR. Obesity and sex steroids during gonadotropin-releasing hormone agonist treatment for prostate cancer. Clin Cancer Res 2007;13:241-5.
2. Periti P, Mazzei T, Mini E. Clinical pharmacokinetics of depot leuprorelin [review]. Clin Pharmacokinet 2002;41:485-504.
3. Akaza H, Aso Y, Koiso K, et al. Leuprorelin acetate depot: results of a multicentre Japanese trial. TAP-144-SR Study Group. J Int Med Res 1990;18 Suppl 1:90-102.
4. Watanabe Y, Nakamura G, Matsuguchi H, Nozaki M, Sano M, Nakano H. Efficacy of a low-dose leuprolide acetate depot in the treatment of uterine leiomyomata in Japanese women. Fertil Steril 1992;558:66-71.
5. Lupron Depot-PED. Package insert. Lake Forest (IL): TAP Pharmaceutical Products, Inc.; 2006.